Validating our approach, Polo-like kinase inhibitors have been extensively used in cancer therapy (Gjertsen and Schöffski, 2014; Shakeel et al., 2021; Zhang et al., 2021) and have also been explored as a potential therapy in combination with MEK inhibitors for the treatment of N-RAS-driven melanoma (Posch et al., 2015). Here, MAP2K7 is linked to cancer.